BACE1 and Alzheimer disease: Therefore, the FA-derivatives that can accumulate into the astrocytes may have clinical relevance at multiple levels in AD: firstly by inhibiting AChE activity and increasing subsequently acetylcholine levels, secondly by inhibiting BACE1 and decreasing Aβ accumulation, and thirdly by reducing both oxidative stress and inflammation which can directly and indirectly inhibit BACE1 activation and the further production of Aβ.